Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (683)	3/17/1999 10:01:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 2001

GLIA hit my last target of $29/share, and then I set a new 12 month target of $34 a couple of months ago. I suspect that GLIA is as strong a takeout candidate as any company out there, and I foresee multiple indications rolling out for both the H(3) antagonist and agonist programs...... I will therefore raise my 12 month target to $60/share. Disclaimer.... that's my target, get your own after doing your own research. GLIA is selling into the "device" market, and that's an area that (1) I'm not particularly familiar with, and (2) appears littered with patent battles.